HM Payson & Co’s Integra LifeSciences IART Stock Holding History

HM Payson & Co’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-29	Closed	-$2K	–	1119
2021 Q3	$2K	Hold	29	–	–	﹤0.01%	1000
2021 Q2	$2K	Hold	29	–	–	﹤0.01%	996
2021 Q1	$2K	Hold	29	–	–	﹤0.01%	1045
2020 Q4	$2K	Buy	+29	New	+$1.56K	﹤0.01%	1015

Other funds holding IART

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HM Payson & Co's IART Position: Q4 2021 in Review

HM Payson & Co sold out of Integra LifeSciences (IART) in Q4 2021, closing a stake of 29 shares — an estimated $2K sold.

HM Payson & Co first reported a position in IART in Q4 2020 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 277 funds tracked by Wall St. Rank hold IART as of Q4 2021.

HM Payson & Co reported no remaining Integra LifeSciences position as of Q4 2021 after selling out during the quarter.
HM Payson & Co sold 29 Integra LifeSciences shares in Q4 2021, an estimated $2K.
HM Payson & Co first reported a position in Integra LifeSciences in Q4 2020 and held it in 4 quarters.
HM Payson & Co's Integra LifeSciences position peaked at $2K in Q3 2021.
277 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2021.

Based on HM Payson & Co's 13F filing for Q4 2021, filed 15 Feb 2022.